Altogether, these results identify AKT signaling as an oncogenic target in ATMKO thymic T-LBL and provide further rationale to investigate inhibitors of the PI3K/AKT/mTOR pathway, particularly AKT inhibitors, in the treatment of human T-ALL. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.